ArticleMolecular pharmaceutics2017
In Vivo Pretargeted Imaging of HER2 and TAG-72 Expression Using the HaloTag Enzyme.
Article in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Preclinical evaluation of a novel tetrazine probe within a pretargeted delivery system for theranostics in HER2-positive tumor-bearing mice models.Acta pharmaceutica Sinica. B · 2026Article
- A PET reporter ligand for quantitative imaging of gene expression in the brain.Nature biomedical engineering · 2026Article
- Bioorthogonal liposome-based sequential drug delivery system for enhanced tumor accumulation and targeted therapy.Drug delivery and translational research · 2026Article
- Head-to-Head Comparison of theMolecular pharmaceutics · 2025Article
- Generation of Site-Specifically Labeled Affinity Reagents via Use of a Self-Labeling Single Domain Antibody.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Recent biomedical advances enabled by HaloTag technology.Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al · 2022Article
- Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Preclinical Evaluation of a NovelACS omega · 2020Article
- Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery.Chemical science · 2020Article
- Highly sensitive electron paramagnetic resonance nanoradicals for quantitative intracellular tumor oxymetric images.International journal of nanomedicine · 2019Article
- Pretargeting of internalizing trastuzumab and cetuximab with aEJNMMI research · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A novel pretargeted SPECT imaging strategy based on the HaloTag enzyme has been evaluated for the first time in a living system. To determine the efficacy of this approach, two clinically relevant cancer biomarkers, HER2 and TAG-72, were selected to represent models of internalizing and noninternalizing antigens, respectively. In MDA-MB-231/H2N (HER2-expressing) and LS174T (TAG-72-expressing) xenograft tumors in mice, pretargeting experiments were performed in which HaloTag-conjugated derivatives of the antibodies trastuzumab (anti-HER2) or CC49 (anti-TAG-72) were utilized as primary agents, and the small molecule HaloTag ligands
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.